Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 2014, 470983

Adult Stem Cell as New Advanced Therapy for Experimental Neuropathic Pain Treatment


Adult Stem Cell as New Advanced Therapy for Experimental Neuropathic Pain Treatment

Silvia Franchi et al. Biomed Res Int.


Neuropathic pain (NP) is a highly invalidating disease resulting as consequence of a lesion or disease affecting the somatosensory system. All the pharmacological treatments today in use give a long lasting pain relief only in a limited percentage of patients before pain reappears making NP an incurable disease. New approaches are therefore needed and research is testing stem cell usage. Several papers have been written on experimental neuropathic pain treatment using stem cells of different origin and species to treat experimental NP. The original idea was based on the capacity of stem cell to offer a totipotent cellular source for replacing injured neural cells and for delivering trophic factors to lesion site; soon the researchers agreed that the capacity of stem cells to contrast NP was not dependent upon their regenerative effect but was mostly linked to a bidirectional interaction between the stem cell and damaged microenvironment resident cells. In this paper we review the preclinical studies produced in the last years assessing the effects induced by several stem cells in different models of neuropathic pain. The overall positive results obtained on pain remission by using stem cells that are safe, of easy isolation, and which may allow an autologous transplant in patients may be encouraging for moving from bench to bedside, although there are several issues that still need to be solved.


Figure 1
Figure 1
Time course of the effect of murine neural stem cells (NSCs) and human adipose derived stem cells (hASC) on thermal hyperalgesia (a), measured by Plantar test, and mechanical allodynia, measured by Dynamic Plantar Aesthesiometer (b), in neuropathic mice. 1 × 106 NSCs/ASCs were injected intravenously 7 days after mice chronic constriction injury; their effect on pain was measured 3, 7, 14, and 21 days after the administration. Data represent mean +/− SEM of 7 mice. The statistical analysis was performed by using the two-way ANOVA analysis of variance followed by Bonferroni test. *P < 0.001 versus Sham, °P < 0.001 versus CCI, and # P < 0.001 versus hASC.

Similar articles

See all similar articles

Cited by 14 PubMed Central articles

See all "Cited by" articles


    1. Treede R-D, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630–1635. - PubMed
    1. Baron R. Mechanisms of disease: Neuropathic pain—a clinical perspective. Nature Clinical Practice Neurology. 2006;2(2):95–106. - PubMed
    1. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. The Lancet Neurology. 2010;9(8):807–819. - PubMed
    1. Sommer C, Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neuroscience Letters. 2004;361(1–3):184–187. - PubMed
    1. Austin PJ, Moalem-Taylor G. The neuro-immune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like glial cells and cytokines. Journal of Neuroimmunology. 2010;229(1-2):26–50. - PubMed